Wassim Kassouf, MD
Research Institute of the McGill University Health Centre
Regular Member Cancer
McGill University Health Centre (MUHC)
Attending Surgeon, Division of Urology, MUHC
Program Director, McGill Urology Residency
My research focuses on various aspects of the biology and therapy in bladder cancer. We investigate mechanisms of resistance through combination therapy and develop novel approaches to sensitize bladder cancer to radiotherapy. Experiments include both in vitro and in vivo animal models as well as human bladder tumors.
- identify molecular markers that are associated with aggressive bladder cancer biology
- radiosensitization of bladder cancer through molecular targets
- novel drug investigations to examine antitumor activity in bladder cancer
- biobanking of tumors, blood, and urine samples to establish predictive models for recurrence and progression of disease
bladder cancer, molecular signalling, therapy, radiosensitization, combination therapy
Nassim R, Mansure JJ, Chevalier S, Cury F, Kassouf W. Combining mTOR Inhibition with Radiation Improves Antitumor Activity in Bladder Cancer Cells In Vitro and In Vivo: A Novel Strategy for Treatment. PLoS One. 2013 Jun 17;8(6):e65257. doi: 10.1371/journal.pone.0065257.
Fahmy M, Mansure JJ, Brimo F, Yafi FA, Segal R, Althunayan A, Hicks J, Meeker A, Netto G, Kassouf W. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer. Hum Pathol. 2013 Sep;44(9):1766-72.
Mansure JJ, Nassim R, Chevalier S, Szymanski K, Rocha J, Aldousari S, Kassouf W. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PLoS One. 2013;8(2):e55997.
Brimo F, Wu C, Zeizafoun N, Tanguay S, Aprikian A, Mansure JJ, Kassouf W. Prognostic factors in T1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol. 44:95-102, 2013.
Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, and Kassouf W. Inhibition on mammalian target of rapamycin as a therapeutic strategy in bladder cancer. Cancer Biol Ther 8(24):2339-47, 2009.